A nationwide study of the economic burden of obstructive hypertrophic cardiomyopathy in France
Obstructive HCM has a high economic burden driven by cardiovascular hospitalizations. Higher disease severity yielded higher costs associated with medical care and sick leave than lower classes. Results support need for new therapies to improve both symptoms and disease severity.
Authors
- Philippe Charron (ORCID: https://orcid.org/0000-0002-1782-1118)
- Aurélie Schmidt
- Jean‐Noël Trochu (ORCID: https://orcid.org/0000-0003-4742-281X)
- Carla Zema
- François-Emery Cotté (ORCID: https://orcid.org/0000-0002-6758-4552)
- Michael Hurst (ORCID: https://orcid.org/0000-0001-9360-0280)
- Arthur Juban
- Julia González
- Taryn Krause (ORCID: https://orcid.org/0009-0009-5681-8497)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Bristol-Myers Squibb (Germany) (DE)
- Lyon College (US)
- Sorbonne Université (FR)
- Bristol-Myers Squibb (United States) (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Bristol-Myers Squibb (France) (FR)
- Pitié-Salpêtrière Hospital (FR)
- Bristol-Myers Squibb (United Kingdom) (GB)
- Bristol-Myers Squibb (Sweden) (SE)
- Institut du Thorax (FR)
- Bristol-Myers Squibb (Italy) (IT)
Publication Details
- Journal
- European Heart Journal - Quality of Care and Clinical Outcomes
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1093/ehjqcco/qcaf096
- Citations
- 1
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Bristol-Myers Squibb